Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

Campos, Marta; Villarroel, Paula González; Fernández, Mercedes Salgado; Gómez, Jesús García; Reinoso, Carlos Romero; Castiñeiras, A. Cousillas; Méndez, J. Méndez; Insua, Yolanda Vidal; Rendo, C. Reboredo; Rúa, Marta Covela; Aldana, G. Quintero; Suárez, Begoña Graña; Maseda, Alberto Carral; Fernández, Mónica Jorge; Augusto, M. Pellón; Ventura, C. Grande; Martín, Elena Gallardo; Montes, Ana; Reboredo-Lopez, M.

doi:10.1093/annonc/mdz155.156

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequent grade 3/4 related toxicities associated with aflibercept were hypertension (5.6%), dysphonia (5.6%), proteinuria (2.8%). Two patients experienced grade 5 toxicity [33]. A real-world analysis of 250 Spanish patients with mCRC treated with aflibercept and irinotecan-based chemotherapy has been conducted.…”

Section: European and The Us Studiesmentioning

confidence: 99%

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

Muro

Salinardi

Singh

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti-epidermal growth factor receptor (EGFR) therapies. Aflibercept, a recombinant fusion protein, has been approved for treatment of mCRC in combination with FOLFIRI for patients whose disease progresses during or after treatment with an oxaliplatin-containing regimen, based on its efficacy and tolerability profile in clinical trials. This report aims to provide an overview of both clinical and real-world evidence and experience on the use of aflibercept in routine clinical practice, with a focus on European, American and Asian populations. Methods: A literature search was conducted in PubMed (on 28th February 2019) using the search terms ("aflibercept") and ("Colorectal"OR"CRC") to identify publications containing information on aflibercept-containing regimens. Results: The adverse events (AE) profile was similar between geographical locations. Across trials, real-world and retrospective studies, grade ≥ 3 hypertension and proteinuria were amongst the most frequently reported AEs. Conclusions: The safety profile of aflibercept is generally manageable and comparable across various geographic locations.

show abstract

Section: European and The Us Studiesmentioning

confidence: 99%